TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: pain assessed on visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Disabilities of the Arm, Shoulder and Hand (DASH) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: hand grip power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Experience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Emotional Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Resolution of esophageal wall defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Need for and use of childcare
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time-to-sustained Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Discontinued Study Intervention Due to an AE
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma exposure of vancomycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the relative abundance of Firmicutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fracture stability assessed via subject-reported pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pathologic complete remission (pCR) after neoadjuvant therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tolerability of treatment as measured by the nature and frequency of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: MgLiTT ablation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cmax ss of Olaparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-τ of Olaparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cornea innervation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blinking reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post Operative Morphine Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Healthy Tooth Surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Carious Tooth Surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highest level of transpulmonary pressure to open up the lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes between the two PEEP level estimated in cmH2O
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Biphasic Alcohol Effects Scale (BAES) - Subscale Sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with PSA decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Rating Score for Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentages of Subjects With Seroresponse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Return of Spontaneous Circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of prothrombotic markers and VEGF variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Area under the GIR profile (AUC GIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systolic BP at Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic BP Measurement at Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in medication use, vital signs, physical examination findings, mental well-being questionnaires, laboratory evaluations, and electrocardiogram results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in serum LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MRE-Derived Shear Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of storage in Fabry cardiomyopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neutrophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: G-CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response to Leucine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of decitabine in CMML treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Release of Vitreo Macular Adhesion (VMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Safety and tolerability of Darifenacin
Endpoint domain: Adverse events/effects
Primary endpoint: HIV RNA Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of oxycodone, oxymorphone, noroxymorphone and noroxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of cerebral hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mortality of stroke associated pneumonia
Endpoint domain: Mortality/survival
Primary endpoint: BOLD activation in hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Type 2 Diabetes Mellitus in GH-treated Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Primary Malignancies in Participant Without Previous Cancer History
Endpoint domain: Adverse events/effects
Primary endpoint: Final Height (FH) Gain by Diagnostic Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of peri-implant inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of gestational diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of ruptured uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Adequate relief of dyspeptic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Treg, Th17, NKT in peripheral blood and tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Value of ROMA in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight estimation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of the treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Inflammatory markers (e.g., TNF-alfa, CRP, fibrinogen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone quality/quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aorta related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Left arm/hand ischemia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in concentration of quinine in tracheal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of the disease measured by Clinical Global Impressions Scale - Severity (CGI-S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Motor Ratings MDS-UPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: elasticity modulus of the leg muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: clinical responsiveness to intra-articular corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Repair site lengthening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient global impression of improvement (PGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Ratio Actual Fraction of Cells Remaining (FCRa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased condom use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vascular density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of cardiovascular diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentration of gantenerumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under ROC curve to predict hypotension and refractory hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dose Limiting Toxicity (DLT) rates
Endpoint domain: Adverse events/effects
Primary endpoint: Liver biopsy results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elastography results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients diagnosed with subseptate uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Adverse Drug Reactions (ADRs) during the study (up to 16 weeks)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Serious Adverse Drug Reactions (SADRs) during the study (up to 16 weeks)
Endpoint domain: Adverse events/effects
Primary endpoint: Days of anti-MRSA antibiotic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total bacteria colony forming units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients successfully completing the study
Endpoint domain: Mortality/survival
Primary endpoint: Assisted Rehabilitation Care (ARC) questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Modified version of Adult Carer Quality of Life Questionnaire (AC-QoL) total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Salivary levels of Streptococcus mutans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Global Esthetic Improvement Scale (GEIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Absolute Change in Ki-67 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pretest probability for HIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-test probability for HIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free from atrial arrhythmia at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Threshold-level tactile detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG tactile evoked response potential (ERP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in stereotypic behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative Opioid Usage
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Rated by Subjects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Initiation of exclusive breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of exclusive breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ex vivo production of pro-inflammatory cytokine IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in total peripheral resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality in cases of obstructed left colonic carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Medication Tolerability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiac functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tolerable dosage of thalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance and Gait improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Simvastatin
Endpoint domain: Adverse events/effects
Primary endpoint: Significant SNPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No emetic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective evaluation of neurostimulation effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence rate of pregnancy complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Relapse of major depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intra and post-operative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Delta-9-tetrahydrocannabinol (THC) Cmax in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rates at week 4 using the 5-point Facial Wrinkle Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Infection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Participant Response to Treatment at Week 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-Related Adverse Events >= Grade 3 On or Before Week 18
Endpoint domain: Adverse events/effects
Primary endpoint: Development of corneal abrasions
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Observed maximum plasma concentration (Cmax) for MD1003
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak Oxygen Consumption (VO2 Max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with treatment success (viral load below 1,000 copies/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and tolerability assessed with NCI toxicity assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate (CR & PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Seroconversion After 1 Dose of Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Seroprotection After 1 Dose of Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Achieving Seroprotection After Second Dose of Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: lung cancer detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postprandial Area under curve from 0 to 4 hours (AUC(0-4)) of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vestibular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Topographic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: CR and Near CR Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemoglobin Increase of Greater or Equal to 5g/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events (TEAE) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Acute change in blood IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acute change in insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute change in glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mortality or worsening rate with need for mechanical ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Morbidity assessed by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Ki67 Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Muscle strength dynamic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Strength isometric
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Standard-of-Care Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concentration of APPs Before Oral Priming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of APPs After Oral Priming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Community point distribution attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Self-installation of ITNs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Household ITN retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Household percentage of ITNs hung
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Household percentage of sleeping spaces covered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients Responders and Non-responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients failing to maintain regression of iris and angle neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Spinal alignment (Cobb angle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in frequency of priapism episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: frequency of HFS
Endpoint domain: Adverse events/effects
Primary endpoint: evaluation of eniluracil dose response
Endpoint domain: Physiological/clinical
Primary endpoint: assessment of any toxicity related to the topical product
Endpoint domain: Adverse events/effects
Primary endpoint: Individual patient compliance with glycemic load index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of grade 2 or more late soft tissue fibrosis
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with 90% of the planPTV receiving 95% of the optimal prescription dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients with 80% of the planPTV receiving 95% of the optimal prescription dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent Change in Peak Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of sexual quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stabilization of the course of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First biopsy-confirmed acute rejection
Endpoint domain: Mortality/survival
Primary endpoint: Brain function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Language processing tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FMT-related adverse events grade 2 or above
Endpoint domain: Adverse events/effects
Primary endpoint: Hormone sensitive Lipase (HSL) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of Paclitaxel induced CIPN-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetics profile assessed by plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of HIV risk screening tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of HIV risk screening tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes